Accelerating drug development
using predictive AI.
Praedicare means “to tell before.” Our AI programs power complex
mathematical representations of disease progression for in silico
to predict future phase III results, today, even for drugs that have
never entered a single animal or patient.
Reduce drug development costs by up to 90%
Accelerate drug development from bench to clinic by 2-3X
Reduce patient death and adverse events by 50%
See into the future
so you won't fall behind.
Our Phase Advance AI™ Program uses mathematics to
model disease progressions, and our AI can predict
individual patient disease trajectory in future phase III trials.
Quantify. Predict. Cure.
Integrating laboratory experiments, mathematical models, morphism mapping, and machine-learning/A.I. to predict:
Rates of Response in Patients
How Many Patients Will Respond
Optimal Duration of Therapy
Doses to Minimize Failure & Resistance
Personalized Therapy
Preclinical Lab & Math
Modeling Solutions
Will drug be efficacious in humans? If so, at what dose? -Are there potential toxicity risks that can be identified early? If so, at what dose?
Are there potential opportunities to improve efficacy through drug combinations? If so, what drug(s) and doses?
How best to align our regulatory strategy, pre- clinical and clinical plans to mitigate risk?
Demonstration of commercial viability of drug to investors & partners
Helping Clients
Our predictions have been highly accurate through Phase III studies and beyond.
Accurately predict efficacy and toxicity signals during preclinical phase
Optimal drug doses for combinations using factorial design
Reduce drug development timelines using our quantitative forecasting
Data and models that we have generated has been used by clients throughout the regulatory process by international regulatory bodies
We can help clients identify potential collaborators and investors
Quantify. Predict. Cure.
Integrating laboratory experiments, mathematical models, morphism mapping, and machine-learning/A.I. to predict:
Rates of Response in Patients
How Many Patients Will Respond
Optimal Duration of Therapy
Doses to Minimize Failure & Resistance
Personalized Therapy
Preclinical Lab & Math
Modeling Solutions
Will drug be efficacious in humans? If so, at what dose? -Are there potential toxicity risks that can be identified early? If so, at what dose?
Are there potential opportunities to improve efficacy through drug combinations? If so, what drug(s) and doses?
How best to align our regulatory strategy, pre- clinical and clinical plans to mitigate risk?
Demonstration of commercial viability of drug to investors & partners
Helping Clients
Our predictions have been highly accurate through Phase III studies and beyond.
Accurately predict efficacy and toxicity signals during preclinical phase
Optimal drug doses for combinations using factorial design
Reduce drug development timelines using our quantitative forecasting
Data and models that we have generated has been used by clients throughout the regulatory process by international regulatory bodies
We can help clients identify potential collaborators and investors
Unique Biotech CRO for Drug Discovery, Development
& Clinical Trials
Customized preclinical model technologies mathematically mapped to patients for quantitative prediction of patient responses, response rates, and optimal doses and toxicology with >90% accuracy.
Model Uses Include:
Optimized clinical trial design, including sample size and adaptive designs
Identify and develop biomarkers to optimize clinical trial design and provide biology-driven clinical trial therapeutic endpoints
Custom-made hollow fiber technology and 3D human organoids combined with advanced ‘omics, bulk and single cell sequencing for drug discovery, biomarkers, IP strengthening/submission, safety, and IND submissions.
INTERESTED IN LEARNING MORE?
Contact Us Today
21
56
Number of Biopharma
Companies Worked With
Number of Projects
Worked On
INTERESTED IN LEARNING MORE?
Contact Us Today
49
Number of Biopharma
Companies Worked With
19
Number of Projects
Worked On